LOX-1 in atherosclerotic disease

Clinica Chimica Acta

Volumn 440, Issue , 2015, Pages 157-163

  Sawamura, Tatsuya ^a   Wakabayashi, Ichiro ^b   Okamura, Tomonori ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

Apolipoprotein B; Atherogenesis; Cardiovascular disease; Endothelial cell; Oxidized low density lipoprotein; Scavenger receptor

Indexed keywords

LIGAND; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOX 1 LIGAND CONTAINING APOB; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; TROPONIN T; UNCLASSIFIED DRUG; APOLIPOPROTEIN B; BIOLOGICAL MARKER; OLR1 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LIFESTYLE; LIPID STORAGE; METABOLIC SYNDROME X; NONHUMAN; OBESITY; REVIEW; SMOKING; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; MALE; METABOLISM; PHYSIOLOGY; RISK FACTOR; STROKE;

ACUTE CORONARY SYNDROME; ANIMALS; APOLIPOPROTEINS B; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; HUMANS; LIFE STYLE; MALE; RISK FACTORS; SCAVENGER RECEPTORS, CLASS E; STROKE;

EID: 84913572966     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.11.016     Document Type: Review

References (85)

1. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989, 320:915-924.
2. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature 2011, 473:317-325.
3. Kodama T., Freeman M., Rohrer L., Zabrecky J., Matsudaira P., Krieger M. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. Nature 1990, 343:531-535.
4. Endemann G., Stanton L.W., Madden K.S., Bryant C.M., White R.T., Protter A.A. CD36 is a receptor for oxidized low density lipoprotein. J Biol Chem 1993, 268:11811-11816.
5. Sawamura T., Kume N., Aoyama T., et al. An endothelial receptor for oxidized low-density lipoprotein. Nature 1997, 386:73-77.
6. Prabhudas M., Bowdish D., Drickamer K., et al. Standardizing scavenger receptor nomenclature. J Immunol 2014, 192:1997-2006.
7. Suzuki H., Kurihara Y., Takeya M., et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997, 386:292-296.
8. Febbraio M., Podrez E.A., Smith J.D., et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000, 105:1049-1056.
9. Inoue K., Arai Y., Kurihara H., Kita T., Sawamura T. Overexpression of lectin-like oxidized low-density lipoprotein receptor-1 induces intramyocardial vasculopathy in apolipoprotein E-null mice. Circ Res 2005, 97:176-184.
10. Mehta J.L., Sanada N., Hu C.P., et al. Deletion of LOX-1 reduces atherogenesis in LDLR knockout mice fed high cholesterol diet. Circ Res 2007, 100:1634-1642.
11. Akhmedov A., Rozenberg I., Paneni F., et al. Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. Eur Heart J 2014, 35:2839-2848.
12. Moore K.J., Kunjathoor V.V., Koehn S.L., et al. Loss of receptor-mediated lipid uptake via scavenger receptor A or CD36 pathways does not ameliorate atherosclerosis in hyperlipidemic mice. J Clin Invest 2005, 115:2192-2201.
13. Manning-Tobin J.J., Moore K.J., Seimon T.A., et al. Loss of SR-A and CD36 activity reduces atherosclerotic lesion complexity without abrogating foam cell formation in hyperlipidemic mice. Arterioscler Thromb Vasc Biol 2009, 29:19-26.
14. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
15. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990, 344:160-162.
16. Cominacini L., Pasini A.F., Garbin U., et al. Oxidized low density lipoprotein (ox-LDL) binding to ox-LDL receptor-1 in endothelial cells induces the activation of NF-kappaB through an increased production of intracellular reactive oxygen species. J Biol Chem 2000, 275:12633-12638.
17. Cominacini L., Rigoni A., Pasini A.F., et al. The binding of oxidized low density lipoprotein (ox-LDL) to ox-LDL receptor-1 reduces the intracellular concentration of nitric oxide in endothelial cells through an increased production of superoxide. J Biol Chem 2001, 276:13750-13755.
18. Chen M., Masaki T., Sawamura T. LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells: implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther 2002, 95:89-100.
19. Sugimoto K., Ishibashi T., Sawamura T., et al. LOX-1-MT1-MMP axis is crucial for RhoA and Rac1 activation induced by oxidized low-density lipoprotein in endothelial cells. Cardiovasc Res 2009, 84:127-136.
20. Besler C., Heinrich K., Rohrer L., et al. Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Invest 2011, 121:2693-2708.
21. Li D., Chen H., Romeo F., Sawamura T., Saldeen T., Mehta J.L. Statins modulate oxidized low-density lipoprotein-mediated adhesion molecule expression in human coronary artery endothelial cells: role of LOX-1. J Pharmacol Exp Ther 2002, 302:601-605.
22. Nagase M., Hirose S., Sawamura T., Masaki T., Fujita T. Enhanced expression of endothelial oxidized low-density lipoprotein receptor (LOX-1) in hypertensive rats. Biochem Biophys Res Commun 1997, 237:496-498.
23. Chen M., Nagase M., Fujita T., Narumiya S., Masaki T., Sawamura T. Diabetes enhances lectin-like oxidized LDL receptor-1 (LOX-1) expression in the vascular endothelium: possible role of LOX-1 ligand and AGE. Biochem Biophys Res Commun 2001, 287:962-968.
24. Chen M., Kakutani M., Minami M., et al. Increased expression of lectin-like oxidized low density lipoprotein receptor-1 in initial atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2000, 20:1107-1115.
25. Morawietz H., Rueckschloss U., Niemann B., et al. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999, 100:899-902.
26. Chen H., Li D., Sawamura T., Inoue K., Mehta J.L. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 2000, 276:1100-1104.
27. Nakano A., Inoue N., Sato Y., et al. LOX-1 mediates vascular lipid retention under hypertensive state. J Hypertens 2010, 28:1273-1280.
28. Li D., Williams V., Liu L., et al. Expression of lectin-like oxidized low-density lipoprotein receptors during ischemia-reperfusion and its role in determination of apoptosis and left ventricular dysfunction. J Am Coll Cardiol 2003, 41:1048-1055.
29. Kataoka K., Hasegawa K., Sawamura T., et al. LOX-1 pathway affects the extent of myocardial ischemia-reperfusion injury. Biochem Biophys Res Commun 2003, 300:656-660.
30. Akamatsu T., Dai H., Mizuguchi M., Goto Y.I., Oka A., Itoh M. LOX-1 is a novel therapeutic target in neonatal hypoxic-ischemic encephalopathy. Am J Pathol 2014, 184:1843-1852.
31. Honjo M., Nakamura K., Yamashiro K., et al. Lectin-like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci U S A 2003, 100:1274-1279.
32. Tang D., Lu J., Walterscheid J.P., et al. Electronegative LDL circulating in smokers impairs endothelial progenitor cell differentiation by inhibiting Akt phosphorylation via LOX-1. J Lipid Res 2008, 49:33-47.
33. Lu J., Yang J.H., Burns A.R., et al. Mediation of electronegative low-density lipoprotein signaling by LOX-1: a possible mechanism of endothelial apoptosis. Circ Res 2009, 104:619-627.
34. Chan H.C., Ke L.Y., Chu C.S., et al. Highly electronegative LDL from patients with ST-elevation myocardial infarction triggers platelet activation and aggregation. Blood 2013, 122:3632-3641.
35. Fujita Y., Kakino A., Nishimichi N., et al. Oxidized LDL receptor LOX-1 binds to C-reactive protein and mediates its vascular effects. Clin Chem 2009, 55:285-294.
36. Fujita Y., Yamaguchi S., Kakino A., Iwamoto S., Yoshimoto R., Sawamura T. Lectin-like oxidized LDL receptor 1 is involved in CRP-mediated complement activation. Clin Chem 2011, 57:1398-1405.
37. Hein T.W., Qamirani E., Ren Y., Xu X., Thengchaisri N., Kuo L. Selective activation of lectin-like oxidized low-density lipoprotein receptor-1 mediates C-reactive protein-evoked endothelial vasodilator dysfunction in coronary arterioles. Circ Res 2014, 114:92-100.
38. Ridker P.M. Establishing a clinical basis for hsCRP in the prevention and treatment of cardiovascular disease. Clin Chem 2010, 56:1186-1187.
39. Celermajer D.S. Reliable endothelial function testing: at our fingertips?. Circulation 2008, 117:2428-2430.
40. Flammer A.J., Anderson T., Celermajer D.S., et al. The assessment of endothelial function: from research into clinical practice. Circulation 2012, 126:753-767.
41. Sato Y., Nishimichi N., Nakano A., et al. Determination of LOX-1-ligand activity in mouse plasma with a chicken monoclonal antibody for ApoB. Atherosclerosis 2008, 200:303-309.
42. Kataoka H., Kume N., Miyamoto S., et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation 1999, 99:3110-3117.
43. Duewell P., Kono H., Rayner K.J., et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361.
44. Kakutani M., Ueda M., Naruko T., Masaki T., Sawamura T. Accumulation of LOX-1 ligand in plasma and atherosclerotic lesions of Watanabe heritable hyperlipidemic rabbits: identification by a novel enzyme immunoassay. Biochem Biophys Res Commun 2001, 282:180-185.
45. Oka K., Yasuhara M., Suzumura K., Tanaka K., Sawamura T. Antioxidants suppress plasma levels of lectinlike oxidized low-density lipoprotein receptor-ligands and reduce atherosclerosis in watanabe heritable hyperlipidemic rabbits. J Cardiovasc Pharmacol 2006, 48:177-183.
46. Ishigaki Y., Katagiri H., Gao J., et al. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 2008, 118:75-83.
47. Nagasawa S.Y., Okamura T., Iso H., et al. Evidence for Cardiovascular Prevention from Observational Cohorts in Japan (EPOCH-JAPAN) Research Group. Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65594 individuals from 10 cohort studies in Japan. J Am Heart Assoc 2012, 1:e001974.
48. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(Suppl. 1):S1-S44.
49. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
50. Teramoto T., Sasaki J., Ishibashi S., et al. Japan Atherosclerosis Society. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb 2013, 20:517-523.
51. Sekikawa A., Curb J.D., Ueshima H., et al. ERA JUMP (Electron-Beam Tomography, Risk Factor Assessment Among Japanese and U.S. Men in the Post-World War II Birth Cohort) Study Group. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol 2008, 52:417-424.
52. Okamura T., Sekikawa A., Kadowaki T., et al. Cholesteryl ester transfer protein, coronary calcium, and intima-media thickness of the carotid artery in middle-age Japanese men. Am J Cardiol 2009, 104:818-822.
53. Okamura T., Sekikawa A., Sawamura T., et al. LOX-1 ligands containing apolipoprotein B and carotid intima-media thickness in middle-aged community-dwelling US Caucasian and Japanese men. Atherosclerosis 2013, 229:240-245.
54. Inoue N., Okamura T., Kokubo Y., et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem 2010, 56:550-558.
55. Tanaka T., Okamura T. Blood cholesterol level and risk of stroke in community-based or worksite cohort studies: a review of Japanese cohort studies in the past 20years. Keio J Med 2012, 61:79-88.
56. Takanabe-Mori R., Ono K., Wada H., et al. Lectin-like oxidized low-density lipoprotein receptor-1 plays an important role in vascular inflammation in current smokers. J Atheroscler Thromb 2013, 20:585-590.
57. Uchida K., Suehiro A., Nakanishi M., Sawamura T., Wakabayashi I. Associations of atherosclerotic risk factors with oxidized low-density lipoprotein evaluated by LOX-1 ligand activity in healthy men. Clin Chim Acta 2011, 412:1643-1647.
58. Brinkley T.E., Kume N., Mitsuoka H., Phares D.A., Hagberg J.M. Elevated soluble lectin-like oxidized LDL receptor-1 (sLOX-1) levels in obese postmenopausal women. Obesity (Silver Spring) 2008, 16:1454-1456.
59. Nomata Y., Kume N., Sasai H., et al. Weight reduction can decrease circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in overweight middle-aged men. Metabolism 2009, 58:1209-1214.
60. Brinkley T.E., Wang X., Kume N., Mitsuoka H., Nicklas B.J. Caloric restriction, aerobic exercise training and soluble lectin-like oxidized LDL receptor-1 levels in overweight and obese post-menopausal women. Int J Obes (Lond) 2011, 35:793-799.
61. Matsumoto T., Fujita M., Sawamura T., et al. Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. Lipids 2010, 45:329-335.
62. Lubrano V., Del Turco S., Nicolini G., Di Cecco P., Basta G. Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. Lipids 2008; 43: 945-50. Metabolism 2013, 62:935-938.
63. Tan K.C., Shiu S.W., Wong Y., Leng L., Bucala R. Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res 2008, 49:1438-1444.
64. Yang C.Z., Zhang Y.Y., Zheng M. Soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in synovial fluid are correlated with disease severity of knee osteoarthritis. Clin Biochem 2011, 44:1094-1096.
65. Okamura T., Sugiyama D., Tanaka T., Dohi S. Worksite wellness for the primary and secondary prevention of cardiovascular disease in Japan: the current delivery system and future directions. Prog Cardiovasc Dis 2014, 56:515-521.
66. Hayashida K., Kume N., Murase T., et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome: a novel marker for early diagnosis. Circulation 2005, 112:812-818.
67. Kobayashi N., Hata N., Kume N., et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 as an early biomarker for ST elevation myocardial infarction: time-dependent comparison with other biomarkers: time-dependent comparison with other biomarkers. Circ J 2011, 75:1433-1439.
68. Kobayashi N., Hata N., Kume N., et al. Soluble lectin-like oxidized LDL receptor-1 and high-sensitivity troponin T as diagnostic biomarkers for acute coronary syndrome. Improved values with combination usage in emergency rooms. Circ J 2011, 75:2862-2871.
69. Kobayashi N., Takano M., Hata N., et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a valuable diagnostic marker for rupture of thin-cap fibroatheroma: verification by optical coherence tomography. Int J Cardiol 2013, 168:3217-3223.
70. Lubrano V., Del Turco S., Nicolini G., Di Cecco P., Basta G. Circulating levels of lectin-like oxidized low-density lipoprotein receptor-1 are associated with inflammatory markers. Lipids 2008, 43:945-950.
71. Balin M., Celik A., Kobat M.A. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are associated with proximal/middle segment of the LAD lesions in patients with stable coronary artery disease. Clin Res Cardiol 2012, 101:247-253.
72. Katritsis D.G., Efstathopoulos E.P., Pantos J., et al. Anatomic characteristics of culprit sites in acute coronary syndromes. J Interv Cardiol 2008, 21:140-150.
73. Kume N., Mitsuoka H., Hayashida K., Tanaka M., Kita T. Soluble lectin-like oxidized low-density lipoprotein receptor-1 predicts prognosis after acute coronary syndrome-a pilot study. Circ J 2010, 74:1399-1404.
74. Balin M., Celik A., Kobat M.A., Baydas A. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI. J Thromb Thrombolysis 2012, 34:483-490.
75. Schwarz D.A., Barry G., Mackay K.B., et al. Identification of differentially expressed genes induced by transient ischemic stroke. Brain Res Mol Brain Res 2002, 101:12-22.
76. Tatsuguchi M., Furutani M., Hinagata J., et al. Oxidized LDL receptor gene (OLR1) is associated with the risk of myocardial infarction. Biochem Biophys Res Commun 2003, 303:247-250.
77. Ohmori R., Momiyama Y., Nagano M., et al. An oxidized low-density lipoprotein receptor gene variant is inversely associated with the severity of coronary artery disease. Clin Cardiol 2004, 27:641-644.
78. Hattori H., Sonoda A., Sato H., et al. G501C polymorphism of oxidized LDL receptor gene (OLR1) and ischemic stroke. Brain Res 2006, 1121:246-249.
79. Fukui M., Tanaka M., Senmaru T., et al. LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes. Metabolism 2013, 62:935-938.
80. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G. TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007, 45(Suppl. S):S5-S67.
81. Kobayashi N., Hata N., Kume N., et al. Detection of acute aortic dissection by extremely high soluble lectin-like oxidized LDL receptor-1 (sLOX-1) and low troponin T levels in blood. Int J Cardiol 2013, 165:557-559.
82. Luo P., Yan M., Frohlich E.D., Mehta J.L., Hu C. Novel concepts in the genesis of hypertension: role of LOX-1. Cardiovasc Drugs Ther 2011, 25:441-449.
83. Yamamoto N., Toyoda M., Abe M., et al. Lectin-like oxidized LDL receptor-1 (LOX-1) expression in the tubulointerstitial area likely plays an important role in human diabetic nephropathy. Intern Med 2009, 48:189-194.
84. Kang B.Y., Hu C., Ryu S., et al. Genomics of cardiac remodeling in angiotensin II-treated wild-type and LOX-1-deficient mice. Physiol Genomics 2010, 42:42-54.
85. Xu X., Hou X., Liang Y., et al. The gene polymorphism of LOX1 predicts the incidence of LVH in patients with essential hypertension. Cell Physiol Biochem 2014, 33:88-96.